Joint pain severity predicts premature discontinuation of aromatase inhibitors in breast cancer survivors

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Chim, Kannie ^a   Xie, Sharon X ^b   Stricker, Carrie T ^c   Li, Qing S ^a   Gross, Robert ^b   Farrar, John T ^b   DeMichele, Angela ^b,c   Mao, Jun J ^a,b,c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Adherence; Adverse effects; Aromatase inhibitor; Breast cancer; Joint pain; Musculoskeletal; Pain diagnosis; Pain management; Survivorship

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; EXEMESTANE; LETROZOLE; TAMOXIFEN;

ADULT; AGED; ARTHRALGIA; ARTICLE; BREAST CANCER; BRIEF PAIN INVENTORY; CANCER SURVIVOR; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG WITHDRAWAL; FEMALE; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD; PAIN ASSESSMENT; PATIENT COMPLIANCE; POSTMENOPAUSE; PREDICTION; PRESCRIPTION; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; SYMPTOMATOLOGY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; ARTHRALGIA; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVORS;

EID: 84883287400     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-401     Document Type: Article

References (25)

1. Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, Jones SE, Alvarez I, Bertelli G, Ortmann O. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. NEJM 2004, 350(11):1081-1092. 10.1056/NEJMoa040331, 15014181.
2. Boccardo F, Rubagotti A, Puntoni M, Guglielmini P, Amoroso D, Fini A, Paladini G, Mesiti M, Romeo D, Rinaldini M. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol 2005, 23(22):5138. 10.1200/JCO.2005.04.120, 16009955.
3. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005, 365(9453):60-62.
4. Thürlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Rabaglio M. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. NEJM 2005, 353(26):2747.
5. Burstein HJ, Prestrud AA, Seidenfeld J, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Malin J. American society of clinical oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 2010, 28(23):3784-3796. 10.1200/JCO.2009.26.3756, 20625130.
6. Hershman DL, Shao T, Kushi LH, Buono D, Tsai WY, Fehrenbacher L, Kwan M, Gomez SL, Neugut AI. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat 2011, 126(2):529-537. 10.1007/s10549-010-1132-4, 3462663, 20803066.
7. Partridge AH, LaFountain A, Mayer E, Taylor BS, Winer E, Asnis-Alibozek A. Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol 2008, 26(4):556-562. 10.1200/JCO.2007.11.5451, 18180462.
8. Dent SF, Gaspo R, Kissner M, Pritchard KI. Aromatase inhibitor therapy: toxicities and management strategies in the treatment of postmenopausal women with hormone-sensitive early breast cancer. Breast Cancer Res Treat 2011, 126(2):295-310. 10.1007/s10549-011-1351-3, 21249443.
9. Henry NL, Azzouz F, Desta Z, Li L, Nguyen AT, Lemler S, Hayden J, Tarpinian K, Yakim E, Flockhart DA. Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. J Clin Oncol 2012, 30(9):936-942. 10.1200/JCO.2011.38.0261, 3341106, 22331951.
10. Kimmick G, Anderson R, Camacho F, Bhosle M, Hwang W, Balkrishnan R. Adjuvant hormonal therapy use among insured, low-income women with breast cancer. J Clin Oncol 2009, 27(21):3445-3451. 10.1200/JCO.2008.19.2419, 2717752, 19451445.
11. Hershman DL, Kushi LH, Shao T, Buono D, Kershenbaum A, Tsai WY, Fehrenbacher L, Lin Gomez S, Miles S, Neugut AI. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol 2010, 28(27):4120-4128. 10.1200/JCO.2009.25.9655, 2953970, 20585090.
12. Neugut AI, Subar M, Wilde ET, Stratton S, Brouse CH, Hillyer GC, Grann VR, Hershman DL. Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancer. J Clin Oncol 2011, 29(18):2534-2542. 10.1200/JCO.2010.33.3179, 3138633, 21606426.
13. Crew KD, Greenlee H, Capodice J, Raptis G, Brafman L, Fuentes D, Sierra A, Hershman DL. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol 2007, 25(25):3877-3883. 10.1200/JCO.2007.10.7573, 17761973.
14. Mao JJ, Stricker C, Bruner D, Xie S, Bowman MA, Farrar JT, Greene BT, DeMichele A. Patterns and risk factors associated with aromatase inhibitor-related arthralgia among breast cancer survivors. Cancer 2009, 115(16):3631-3639. 10.1002/cncr.24419, 3569524, 19517460.
15. Mao JJ, Chung A, Benton A, Hill S, Ungar L, Leonard CE, Hennessy S, Holmes JH. Online discussion of drug side effects and discontinuation among breast cancer survivors. Pharmacoepidemiol Drug Saf 2013, 22(3):256-262. 10.1002/pds.3365, 23322591.
16. Mao JJ, Su HI, Feng R, Donelson ML, Aplenc R, Rebbeck TR, Stanczyk F, DeMichele A. Association of functional polymorphisms in CYP19A1 with aromatase inhibitor associated arthralgia in breast cancer survivors. Breast Cancer Res 2011, 13:R8. 10.1186/bcr2813, 3109575, 21251330.
17. Guth U, Myrick ME, Kilic N, Eppenberger-Castori S, Schmid SM. Compliance and persistence of endocrine adjuvant breast cancer therapy. Breast Cancer Res Treat 2011, 131(2):491-499.
18. Cleeland C, Ryan K. Pain assessment: global use of the brief pain inventory. Ann Acad Med Singapore 1994, 23(2):129-138.
19. Grossman SA, Sheidler VR, Swedeen K, Mucenski J, Piantadosi S. Correlation of patient and caregiver ratings of cancer pain. J Pain Symptom Manag 1991, 6(2):53-57.
20. Rhodes DJ, Koshy RC, Waterfield WC, Wu AW, Grossman SA. Feasibility of quantitative pain assessment in outpatient oncology practice. J Clin Oncol 2001, 19(2):501-508.
21. Swarm R, Abernethy AP, Anghelescu DL, Benedetti C, Blinderman CD, Boston B, Cleeland C, Coyle N, Eilers JG, Ferrell B. Adult cancer pain. J Natl Compr Canc Netw 2010, 8(9):1046-1086.
22. Berry DL, Blumenstein BA, Halpenny B, Wolpin S, Fann JR, Austin-Seymour M, Bush N, Karras BT, Lober WB, McCorkle R. Enhancing patient-provider communication with the electronic self-report assessment for cancer: a randomized trial. J Clin Oncol 2011, 29(8):1029-1035. 10.1200/JCO.2010.30.3909, 3068053, 21282548.
23. Mao JJ, Bruner DW, Stricker C, Farrar JT, Xie SX, Bowman MA, Pucci D, Han X, DeMichele A. Feasibility trial of electroacupuncture for aromatase inhibitor-related arthralgia in breast cancer survivors. Integr Cancer Ther 2009, 8(2):123-129. 10.1177/1534735409332903, 3569528, 19679620.
24. Crew KD, Capodice JL, Greenlee H, Brafman L, Fuentes D, Awad D, Tsai WY, Hershman DL. Randomized, blinded, sham-controlled trial of acupuncture for the management of aromatase inhibitor-associated joint symptoms in women with early-stage breast cancer. J Clin Oncol 2010, 28(7):1154-1160. 10.1200/JCO.2009.23.4708, 20100963.
25. Khan QJ, Reddy PS, Kimler BF, Sharma P, Baxa SE, ODea AP, Klemp JR, Fabian CJ. Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer. Breast Cancer Res Treat 2010, 119(1):111-118. 10.1007/s10549-009-0495-x, 19655244.